BioStock: Immunicum publishes DCP-001 data

Thanks to the merger with DCPrime, Swedish immuno-oncology company Immunicum added DCP-001 to its clinical development programme – a cancer relapse vaccine aimed at preventing tumour recurrence. The candidate is currently in the phase II programme in patients with acute myeloid leukaemia, and, this week, the company has announced the publication of a scientific journal article describing the mechanism of action for DCP-001. The data shows that the cancer relapse vaccine provides active immunization and a durable anti-tumour immune response.

Read the article at biostock.se:

https://www.biostock.se/en/2021/11/immunicum-publishes-dcp-001-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se